Roche: hemophilia drug shows positive results in children
(CercleFinance.com) - Roche's Hemlibra provided sustained bleed control in a large pivotal study on children with hemophilia, the Swiss drugmaker said on Tuesday.
Roche today unveiled data from a phase III study evaluating Hemlibra prophylaxis in children under 12 with haemophilia A with factor VIII inhibitors.
Data shows that nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds, Roche said.
At the American Society of Hematology annual meeting, the Basel-based company also said that new data on blood cancer drug Venclexta/Venclyxto demonstrated "deep responses" in two of the most common types of leukemia.
In particular, new analyses from a phase III study in previously treated chronic lymphocytic leukaemia showed continued benefit from fixed-duration regimen after a median follow-up of three years, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Roche today unveiled data from a phase III study evaluating Hemlibra prophylaxis in children under 12 with haemophilia A with factor VIII inhibitors.
Data shows that nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds, Roche said.
At the American Society of Hematology annual meeting, the Basel-based company also said that new data on blood cancer drug Venclexta/Venclyxto demonstrated "deep responses" in two of the most common types of leukemia.
In particular, new analyses from a phase III study in previously treated chronic lymphocytic leukaemia showed continued benefit from fixed-duration regimen after a median follow-up of three years, Roche said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.